PRESSEMITTEILUNGEN

Hatfield, England (ots/PRNewswire) – Die Europäische Arzneimittelagentur (EMA) hat die EU-Marktzulassung (Marketing Authorisation Approval (MAA)) für einmal täglich einzunehmendes Zonegran(R) (Zonisamid) als Monotherapie für die Behandlung von fokalen Anfällen (mit oder ohne sekundäre Generalisierung) bei Erwachsenen mit neu diagnostizierter Epilepsie erteilt. Bisher war das Medikament bereits als Zusatztherapie für fokale Anfälle zugelassen. Zonisamid ist ein [...]

Continue reading

Als, Bettina Bauer, Die Eu, Ein, Eisai, England, Epilepsie, Erwachsenen, Frankreich, Hatfield, Hopital Pitié SalpêTrièRe, Kommentiert, Marketing, Mit Oder, Ots, Paris, Zonegran

Hatfield, England (ots/PRNewswire) – Reimbursement granted for Zebinix(R) as adjunctive therapy for adults with partial-onset seizures Eisai Europe Limited announces the launch of Zebinix(R) (eslicarbazepine acetate) in France. Upon launch, this novel epilepsy drug will receive full reimbursements from the French health authorities. Once-daily eslicarbazepine acetate is indicated as an adjunctive (add-on) therapy for adults [...]

Continue reading

Armamentarium, Bettina Bauer, Comorbidities, Consultant Neurologist, Eisai, Epilepsy Patients, Epilepsy Treatment, Eslicarbazepine, Europe Limited, French Health, Generalisation, Health Authorities, Health Care Mission, Human Health Care, Partial Onset Seizures, Poor Health, Prnewswire, Uncontrollable Seizures, Uncontrolled Seizures, Welcome Addition

Hatfield, England (ots/PRNewswire) – Eisai today announced that the European Medicines Agency (EMA) has accepted for review their application to extend the use of zonisamide as monotherapy for newly diagnosed epilepsy patients with partial seizures, with and without second generalisation. Zonisamide is a second generation anti-epileptic drug with multiple mechanisms of action, with a chemical [...]

Continue reading

Adjunctive Therapy, Anti Epileptic Drugs, Bettina Bauer, Cbz, Chemical Structure, Eisai, Epilepsy Patients, Epileptic Drug, European Medicines, Extension Application, Living With Epilepsy, Medicines Agency, Monotherapy, Neurological Conditions, Partial Epilepsy, Partial Seizures, Pharmacokinetic Properties, Prnewswire, Today Announced That, Zonisamide

Hatfield, England (ots/PRNewswire) – Zebinix(R) (eslicarbazepine acetate), an add-on (adjunctive) therapy for adults with partial-onset seizures, with or without secondary generalisation (where the seizure extensively affects consciousness of the patients by propagation to both sides of the brain), has recently been launched in Greece by Arriani Pharmaceuticals, Eisai’s chosen partner in Greece. In April 2009, [...]

Continue reading

Acetat, Anti Epileptic Drugs, Bettina Bauer, Eisai, Epilepsy, Eslicarbazepine, Generalisation, Germany Austria, Health Care Mission, Human Health Care, Launch, Neurological Diseases, Norway Iceland, Partial Onset Seizures, Partial Seizures, Prnewswire, Republic Of Ireland, Seizure Control, Seizure Frequency, Sides Of The Brain

Hatfield, England (ots/PRNewswire) – Zebinix(R) (eslicarbazepine acetate), an add-on (adjunctive) therapy for adults with partial-onset seizures, with or without secondary generalisation (where the seizure spreads to both sides of the brain), has been launched today in Spain by Eisai and BIAL in a co-promotion. In 2009, the European Commission approved Zebinix based on data showing [...]

Continue reading

Anti Epileptic Drugs, Bettina Bauer, Bial, Business Development Director, Eisai, Epilepsy, Eslicarbazepine, European Footprint, Generalisation, Germany Austria, Launch, Neurological Diseases, Norway Iceland, Partial Onset Seizures, Partial Seizures, Prnewswire, Seizure Control, Seizure Frequency, Therapeutic Area, Therapeutic Option